

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

28 Jun 2026

### The comparison between effect polyethylene glycol (PEG) Along with Bacillus coagulans (probiotic) with effect polyethylene glycol (PEG) in treatment of functional constipation in Childrens referred to pediatric gastroenterology clinic of Shiraz University of Medical Sciences

#### Protocol summary

##### Summary

Abstract : The purpose was to compare the effect of probiotic with polyethylene glycol and polyethylene glycol alone for the treatment of functional constipation in children. Design: In this study children with functional constipation randomly allocated into two groups. To the first group was given polyethylene glycol and second group was given probiotic and polyethylene glycol. After 6 weeks, probiotic was added to group1 and removed from group2 medication. The study fallowed for more six weeks. The results of 4th week were compared with 1th week, and the results of 10th week were compared with 7th week in each groups. The data of 4th and 10th weeks were also compared between both groups. How do: Number of 80 children with functional constipation were enrolled in the study (40 for each group). Before treatment, basic information (stool frequency, stool consistency, fecal incontinence, abdominal pain, pain during defecation) were recorded. During the study, daily symptoms were recorded by the standard form. The data collected during the study were analyzed by SPSS software. Participants including major eligibility criteria: Inclusion criteria: children with functional constipation (Rome III criteria) Exclusion criteria: use of other medication for functional constipation except polyethylene glycol in 1 last month; The presence of organic cause; Dissatisfaction of parents or Patient Intervention: Use of probiotic of Bacillus Coagulans as adjuvant treatment of functional constipation by adding to polyethylene glycol The main outcome variable: The mean stool frequency, stool consistency, fecal incontinence, abdominal pain, pain during defecation.

#### General information

##### Acronym

#### IRCT registration information

IRCT registration number: **IRCT138812222434N3**

Registration date: **2015-05-10, 1394/02/20**

Registration timing: **retrospective**

Last update:

Update count: **0**

#### Registration date

2015-05-10, 1394/02/20

#### Registrant information

##### Name

Mohammad Hadi Imanieh

##### Name of organization / entity

Shiraz University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 71 1647 4298

##### Email address

imaniehm@sums.ac.ir

#### Recruitment status

##### Recruitment complete

#### Funding source

vice chancellor for research shiraz university of medical sciences

#### Expected recruitment start date

2013-09-23, 1392/07/01

#### Expected recruitment end date

2014-04-17, 1393/01/28

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

## Scientific title

The comparison between effect polyethylene glycol (PEG) Along with Bacillus coagulans (probiotic) with effect polyethylene glycol (PEG) in treatment of functional constipation in Childrens referred to pediatric gastroenterology clinic of Shiraz University of Medical Sciences

## Public title

Comparison of effect of probiotic with polyethylene glycol,with polyethylene glycol alone in the treatment of functional constipation in children

## Purpose

Treatment

## Inclusion/Exclusion criteria

Inclusion criteria:All pediatric patient with constipation that fulfilled Rome III criteria for functional constipation without any treatment;All pediatric patient with constipation that fulfilled Rome III criteria for functional constipation without clinical response to polyethylene glycol (PEG) Exclusion criteria:patients received other drugs for constipation except polyethylene glycol (PEG); The presence of organic cause; Dissatisfaction of parents or Patient

## Age

From **1 month** old to **18 years** old

## Gender

Both

## Phase

2-3

## Groups that have been masked

*No information*

## Sample size

Target sample size: **80**

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Not blinded

## Blinding description

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Medical Ethics Committee of Shiraz University of Medical Sciences

##### Street address

Shiraz University of Medical Sciences(central building), Zand Street, Shiraz, Fars

##### City

Shiraz

#### Postal code

#### Approval date

2013-09-28, 1392/07/06

#### Ethics committee reference number

ct-p-9355-5585

## Health conditions studied

### 1

#### Description of health condition studied

constipation

#### ICD-10 code

k59.0

#### ICD-10 code description

Retention,retained-fecal

## Primary outcomes

### 1

#### Description

stool frequency

#### Timepoint

1th week.4thweek.7thweek and 10th week

#### Method of measurement

recorded through questionnaires

### 2

#### Description

stool incontinence

#### Timepoint

1th week.4thweek.7thweek and 10th week

#### Method of measurement

recorded through questionnaires

### 3

#### Description

stool consistency

#### Timepoint

1th week.4thweek.7thweek and 10th week

#### Method of measurement

recorded through questionnaires

### 4

#### Description

abdominal pain

#### Timepoint

1th week.4thweek.7thweek and 10th week

#### Method of measurement

recorded through questionnaires

### 5

#### Description

pain on defecation

#### Timepoint

1th week.4thweek.7thweek and 10th week

**Method of measurement**

recorded through questionnaires

**Secondary outcomes****1****Description**

drug adverse effects and clinical response

**Timepoint**

6th week and 12th week

**Method of measurement**

recoded through questionnaires

**2****Description**

Evaluation of Clinical response on stool frequency

**Timepoint**

1th week.4thweek.7thweek and 10th week

**Method of measurement**

recoded through questionnaires

**3****Description**

Evaluation of Clinical response on Fecal incontinence

**Timepoint**

1th week.4thweek.7thweek and 10th week

**Method of measurement**

recoded through questionnaires

**4****Description**

Evaluation of Clinical response on stool Consistency

**Timepoint**

1th week.4thweek.7thweek and 10th week

**Method of measurement**

recoded through questionnaires

**5****Description**

Evaluation of clinical response of pain during defecation

**Timepoint**

1th week.4thweek.7thweek and 10th week

**Method of measurement**

recoded through questionnaires

**6****Description**

Evaluation of Clinical response on abdominal pain

**Timepoint**

1th week.4thweek.7thweek and 10th week

**Method of measurement**

recoded through questionnaires

**Intervention groups****1****Description**

PEG solution 40% : 0.5gr/kg/dose TID Cap probiotic:  
1.5\*10<sup>9</sup> CFU TID

**Category**

Treatment - Drugs

**2****Description**

PEG solution 40% : 0.5gr/kg/dose TID for 6 week

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Pediatric GI clinic, Imam Reza clinic

**Full name of responsible person**

Ali keshtkari

**Street address**

Imam Reza clinic, Namazi Square, Zand street, Shiraz,  
Fars

**City**

Shiraz

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Shiraz University of Medical Sciences, vice chancellor  
for research

**Full name of responsible person**

Dr Basir Hashemi

**Street address**

Shiraz university of medical sciences(central  
building), Zand Street, Shiraz, Fars

**City**

Shiraz

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shiraz University of Medical Sciences, vice chancellor for  
research

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**  
*empty*

+98 71136474298

**Fax**

**Email**

imaniehm@sums.ac.ir

**Web page address**

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Ali Keshtkari

**Position**

Fellowship of Pediatric Gastroenterology

**Other areas of specialty/work**

**Street address**

Pediatric GI ward, Nammazi Hospital, Shiraz, Fars

**City**

Shiraz

**Postal code**

**Phone**

00

**Fax**

**Email**

keshtkari@sums.ac.ir

**Web page address**

## Person responsible for updating data

### Contact

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Ali Keshtkari

**Position**

Fellowship of Pediatric Gastroenterology

**Other areas of specialty/work**

**Street address**

Pediatric GI ward, Nammazi Hospital, Shiraz, Fars

**City**

Shiraz

**Postal code**

**Phone**

00

**Fax**

**Email**

keshtkari@sums.ac.ir

**Web page address**

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Mohammad Hadi Imanieh

**Position**

Professor of Pediatric Gastroenterology

**Other areas of specialty/work**

**Street address**

Pediatric GI ward, Department of Pediatric, Nammazi Hospital, Shiraz, Fars

**City**

Shiraz

**Postal code**

**Phone**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*